Literature DB >> 27175788

PAX8 is transcribed aberrantly in cervical tumors and derived cell lines due to complex gene rearrangements.

Eduardo López-Urrutia1, Abraham Pedroza-Torres2, Jorge Fernández-Retana2, David Cantu De Leon3, Fermín Morales-González4, Nadia Jacobo-Herrera5, Oscar Peralta-Zaragoza6, Jorge García-Mendez7, Verónica García-Castillo1, Osvaldo Bautista-Isidro1, Carlos Pérez-Plasencia1.   

Abstract

The transcription factor PAX8, a member of the paired box-containing gene family with an important role in embryogenesis of the kidney, thyroid gland and nervous system, has been described as a biomarker in tumors of the thyroid, parathyroid, kidney and thymus. The PAX8 gene gives rise to four isoforms, through alternative mRNA splicing, but the splicing pattern in tumors is not yet established. Cervical cancer has a positive expression of PAX8; however, there is no available data determining which PAX8 isoform or isoforms are present in cervical cancer tissues as well as in cervical carcinoma-derived cell lines. Instead of a differential pattern of splicing isoforms, we found numerous previously unreported PAX8 aberrant transcripts ranging from 378 to 542 bases and present in both cervical carcinoma-derived cell lines and tumor samples. This is the first report of PAX8 aberrant transcript production in cervical cancer. Reported PAX8 isoforms possess differential transactivation properties; therefore, besides being a helpful marker for detection of cancer, PAX8 isoforms can plausibly exert differential regulation properties during carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27175788     DOI: 10.3892/ijo.2016.3515

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  1 in total

1.  Paired box 8 suppresses tumor angiogenesis and metastasis in gastric cancer through repression of FOXM1 via induction of microRNA-612.

Authors:  Liyan Wang; Xiaotong Bo; Qinghua Zheng; Wenhong Ge; Yanhua Liu; Bin Li
Journal:  J Exp Clin Cancer Res       Date:  2018-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.